The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
The costs associated with the care of Alzheimer's disease patients are very high, particularly those associated with nursing home placement. The combination of a cholinesterase inhibitor (ChEI) and memantine has been shown to significantly delay admission to nursing homes as compared to treatment with a ChEI alone. The objective of this cost-effectiveness analysis was to evaluate the economic impact of the concomitant use of memantine and ChEI compared to ChEI alone. Markov modelling was used in order to simulate transitions over time among three discrete health states (non-institutionalised, institutionalised and deceased). Transition probabilities were obtained from observational studies and French national statistics, utilities from a previous US survey and costs from French national statistics. The analysis was conducted from societal and healthcare system perspectives. Mean time to nursing home admission was 4.57 years for ChEIs alone and 5.54 years for combination therapy, corresponding to 0.98 additional years, corresponding to a gain in quality adjusted life years (QALYs) of 0.25. From a healthcare system perspective, overall costs were €98,609 for ChEIs alone and €90,268 for combination therapy, representing cost savings of €8,341. From a societal perspective, overall costs were €122,039 and €118,721, respectively, representing cost savings of €3,318. Deterministic and probabilistic (Monte Carlo simulations) sensitivity analyses indicated that combination therapy would be the dominant strategy in most scenarios. In conclusion, combination therapy with memantine and a ChEI is a cost-saving alternative compared to ChEI alone as it is associated with lower cost and increased QALYs from both a societal and a healthcare perspective.
Faculty of Medicine, University of Montpellier, Montpellier, France.
Jacques
J
Touchon
Jean
J
Lachaine
Catherine
C
Beauchemin
Anna
A
Granghaud
Benoit
B
Rive
Sébastien
S
Bineau
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D005260:Female; D005602:France / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008390:Markov Chains; D008559:Memantine / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D009735:Nursing Homes / Q000191:economics* / Q000706:statistics & numerical data; D011336:Probability; D019057:Quality-Adjusted Life Years; D016019:Survival Analysis
D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D008559:Memantine